If you understand the meaning of the expression "better than a poke in the eye with a sharp stick," you can appreciate why investors are backing fledgling PanOptica Inc. with $30 million in Series A financing. Read More
Shares of Inspire Pharmaceuticals Inc. fell 58.7 percent Monday after the firm said cystic fibrosis drug denufosol failed to meet its primary and secondary endpoints in a Phase III trial. Read More
LONDON – Neurosearch said it intends to press ahead and present the data on its Huntington's disease treatment Huntexil (pridopine) to regulators, following a meta-analysis of two studies that each individually failed to meet the primary endpoint. Read More
Results from two Phase III studies of nalmefene for alcohol dependence showed that some alcoholics really can quit any time they want. Nalmefene is a small-molecule opioid receptor antagonist that reduces an alcohol-dependent person's desire to drink. A unique feature of the drug in that therapeutic category is that abstinence from alcohol is not necessary for treatment success. Nalmefene is being developed by Biotie Therapies Corp., of Turku, Finland, and is licensed to H. Lundbeck A/S, of Copenhagen, Denmark. Read More
Epicept Corp., of Tarrytown, N.Y., regained compliance with Nasdaq's listing qualifications for continued listing on the Nasdaq Capital Market. Read More
BioLineRx Ltd., of Jerusalem, reported positive results from a Phase I/II trial of BL-5010, a formulation for nonsurgical removal of skin lesions. Read More
